Does UPADACITINIB Cause Basal cell carcinoma? 294 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 294 reports of Basal cell carcinoma have been filed in association with UPADACITINIB (Rinvoq). This represents 0.5% of all adverse event reports for UPADACITINIB.
294
Reports of Basal cell carcinoma with UPADACITINIB
0.5%
of all UPADACITINIB reports
1
Deaths
24
Hospitalizations
How Dangerous Is Basal cell carcinoma From UPADACITINIB?
Of the 294 reports, 1 (0.3%) resulted in death, 24 (8.2%) required hospitalization, and 2 (0.7%) were considered life-threatening.
Is Basal cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for UPADACITINIB. However, 294 reports have been filed with the FAERS database.
What Other Side Effects Does UPADACITINIB Cause?
Pain (4,444)
Arthralgia (3,815)
Drug ineffective (3,384)
Covid-19 (2,978)
Rheumatoid arthritis (2,730)
Pain in extremity (2,353)
Fatigue (2,153)
Fall (2,081)
Surgery (2,037)
Therapy interrupted (1,741)
What Other Drugs Cause Basal cell carcinoma?
ADALIMUMAB (1,547)
INFLIXIMAB (1,340)
METHOTREXATE (1,268)
RITUXIMAB (1,085)
ETANERCEPT (998)
ABATACEPT (852)
TOCILIZUMAB (761)
LENALIDOMIDE (685)
HYDROXYCHLOROQUINE (662)
LEFLUNOMIDE (657)
Which UPADACITINIB Alternatives Have Lower Basal cell carcinoma Risk?
UPADACITINIB vs URAPIDIL
UPADACITINIB vs UREA
UPADACITINIB vs URIDINE TRIACETATE
UPADACITINIB vs UROFOLLITROPIN
UPADACITINIB vs URSODIOL